Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 5/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043319 | 0.84 | MAOA (0.40) | FADS1MAOAFFAR4PDE3BPDE3A | |
| SCHEMBL3039862 | 0.83 | MAOA (0.42) | FADS1MAOAFFAR4PDE3BPDE3A | |
| SCHEMBL3039863 | 0.83 | MAOA (0.39) | FADS1MAOAPDE3BPDE3A | |
| SCHEMBL3041907 | 0.76 | FADS1 (0.31) | FADS1MAOA | |
| SCHEMBL3041904 | 0.76 | FADS1 (0.31) | FADS1MAOA | |
| SCHEMBL3043513 | 0.74 | FADS1 (0.36) | FADS1 | |
| SCHEMBL5764017 | 0.73 | MAOA (0.60) | FADS1MAOAGRM2 | |
| SCHEMBL6690220 | 0.73 | MAOA (0.43) | FADS1MAOAPDE3BPDE3A | |
| SCHEMBL3041105 | 0.72 | FADS1 (0.33) | FADS1 | |
| SCHEMBL3048219 | 0.70 | FADS1 (0.32) | FADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | FADS1 2487/4885MAOA 957/4885FFAR4 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.